Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anetumab Ravtansine vs Vinorelbine in Advanced Mesothelioma
NCT02610140Phase 2Completed
- Sponsor
- Bayer
- Start
- Dec 2015
- Primary completion
- May 2017
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 14
01
Overview
A Phase 2 trial of anetumab ravtansine in malignant pleural mesothelioma (MPM), sponsored by Bayer. Started Dec 2015; status: completed.
02
Drugs
anetumab ravtansine
03
Conditions
malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT02610140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02610140.